All In Biotech

Drug Trial Radar · NCT07434050

A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy and Safety of XW003 Injections in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy

Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Mar 2, 2026

Primary completion

Jun 19, 2028

Study completion Jun 19, 2028

Sponsor

Sponsor type
Industry
First posted
Feb 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to assess the efficacy and safety of XW003 injections in obese participants with OSA receiving PAP

Conditions

  • OSA - Obstructive Sleep Apnea
  • Obesity

Interventions

  • XW003 injectionDrug

    subcutaneous injection

  • placebo with matching volumeDrug

    subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Apnea-Hypopnea Index (AHI)Time frame: at week 48

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Rui Jin Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.